Page last updated: 2024-11-13
landomycin e
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
landomycin E: structure given in first source; isolated from Streptomyces sp. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 53297398 |
CHEBI ID | 81891 |
MeSH ID | M0293299 |
Synonyms (4)
Synonym |
---|
landomycin e |
C18685 |
CHEBI:81891 |
Q27155649 |
Research Excerpts
Overview
Landomycin E (LE) is an angucycline antibiotic produced by Streptomyces globisporus.
Excerpt | Reference | Relevance |
---|---|---|
"Landomycin E (LE) is an angucycline antibiotic produced by Streptomyces globisporus. " | ( Rapid generation of hydrogen peroxide contributes to the complex cell death induction by the angucycline antibiotic landomycin E. Berger, W; Downey, T; Heffeter, P; Herbacek, I; Jha, AK; Kril, IJ; Lehka, LV; Matselyukh, BP; Panchuk, RR; Rohr, J; Stoika, RS; Terenzi, A; van Schoonhoven, S, 2017) | 2.11 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
oligosaccharide | A compound in which monosaccharide units are joined by glycosidic linkages. The term is commonly used to refer to a defined structure as opposed to a polymer of unspecified length or a homologous mixture. When the linkages are of other types the compounds are regarded as oligosaccharide analogues. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (26)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 19 (73.08) | 29.6817 |
2010's | 7 (26.92) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 10.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.60) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (2.44%) | 6.00% |
Case Studies | 1 (2.44%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 39 (95.12%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |